Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer
- Jakub Liu
- Magdalena Mroczek
- Anna Mach
- Maria Stępień
- Angelika Aplas
- Bartosz Pronobis-Szczylik
- Szymon Bukowski
- Magda Mielczarek
- Ewelina Gajewska
- Piotr Topolski
- Zbigniew J. Król
- Joanna Szyda
- Paula Dobosz
DOIAbstract
The number of cases of pancreatic cancers in 2019 in Poland was 3852 (approx. 2% of all cancers). The course of the disease is very fast, and the average survival time from the diagnosis is 6 months. Only <2% of patients live for 5 years from the diagnosis, 8% live for 2 years, and almost half live for only about 3 months. A family predisposition to pancreatic cancer occurs in about 10% of cases. Several oncogenes in which somatic changes lead to the development of tumours, including genes BRCA1/2 and PALB2, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1, are involved in pancreatic cancer. Between 4% and 10% of individuals with pancreatic cancer will have a mutation in one of these genes. Six percent of patients with pancreatic cancer ...
Add to ORKG